Investor relations

Investor relations

Our science-led strategy is key to delivering long-term value for patients, employees and shareholders.

NYSE: MRK
November 30, 2021 10:10 am ET
Delayed at least 20 minutes

Latest news, events & financials

November 30, 2021

Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan in Combination With Chemotherapy for First-Line Treatment of Patients With Radically Unresectable, Advanced or Recurrent Esophageal Carcinoma

November 30, 2021

FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority Review

November 29, 2021

European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) for Patients With Certain Types of Endometrial Carcinoma

View all

December 01, 2021

Featured

Merck & Co., Inc. at the 4th Annual Evercore ISI HealthCONx Conference

Add to Calendar Webcast

February 03, 2022

Earnings

Merck & Co., Inc. Q4 2021 Earnings Call

Add to Calendar

April 28, 2022

Earnings

Merck & Co., Inc. Q1 2022 Earnings Call

Add to Calendar

July 28, 2022

Earnings

Merck & Co., Inc. Q2 2022 Earnings Call

Add to Calendar

View all

3Q21 Merck Earnings Announcement
PDF

3Q21 Merck Other Financial Disclosures
PDF

View all

Merck & Co., Inc. at the 4th Annual Evercore ISI HealthCONx Conference

Add to Calendar

Webcast

See full agenda

Our pipeline shows our relentless pursuit of the next breakthrough.

Explore our pipeline

Phase II programs

Phase III programs

Under review

Our leadership

Our deep bench of talent has the knowledge, commitment and expertise to successfully execute on our innovation strategy.

Leadership

Corporate responsibility

Supporting the future of our business and the health and well-being of patients, people and communities around the world.

Download our 2020/2021 ESG Progress Report

We're led by our science

We follow the science to our next breakthrough, leaving no stone unturned.

View our stories

Innovation

Our third-quarter 2021 financial results

Merck announced third-quarter 2021 worldwide sales of $13.2 billion, 20% above third-quarter 2020. Excluding the impact from foreign exchange, sales grew 19%. The company anticipates full-year 2021 revenue range to be between $47.4 billion and $47.9 billion, including a positive impact from foreign exchange of approximately 1.5%. Take a look at the infographic below for […]

Next: Our third-quarter 2021 financial results